The firm will use the proceeds to continue developing its Proteograph platform, build its proteomic database, and develop liquid biopsy products for early disease detection.
The company will market Inivata's InVision liquid biopsy assays to insured and self-pay patients across the region.
The British team believes its classifier can identify men who will need treatment within five years, minimizing the need of repeated checkups for low-risk patients.
An increased blood-to-stool ratio in the concentration of bacterial short-chain fatty acids marked higher permeability in the intestinal wall.
Guardant told a federal judge that it believes Foundation Medicine and Personal Genome Diagnostics are coordinating to invalidate its patents.